<div><p>German drugmaker Boehringer Ingelheim and Vitae Pharmaceuticals say they are partnering to develop enzyme-inhibiting drugs with the potential to slow or even halt progression of Alzheimer's disease.</p><p>The deal could be worth roughly $250 million to Vitae, a small, development-stage pharmaceutical company based in Fort Washington, Pa ...